Collectively, these findings indicate that ARHGEF12 regulates cisplatin resistance in bladder cancer cells and underscore the precision of combining MR analysis with single-cell approaches to pinpoint candidate therapeutic targets. The gene discussed is ARHGEF12; the disease is urinary bladder carcinoma.